Month: May 2024

Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

Written by Customer Service on May 9, 2024. Posted in Earnings Releases And Operating Results.

MRT-2359, a molecular glue degrader (MGD) being developed for MYC-driven solid tumors, advancing in ongoing Phase 1/2 clinical trial; determination of recommended Phase 2 dose expected in Q2 2024; Phase 1 clinical data anticipated in H2 2024 MRT-6160, a VAV1-directed MGD in development for systemic and neurological autoimmune diseases, on track toward expected IND submission in Q2 2024 and initiation of Phase 1 SAD/MAD study mid-year; Phase 1 clinical data expected in Q1 2025 MRT-8102, a first-in-class NEK7-directed MGD and NLRP3/IL-1β pathway inhibitor, demonstrated efficient blood-brain barrier penetration and CNS activity in non-human primates (NHPs); IND submission on track for Q1 2025 New discovery program unveiled for CCNE1-directed MGDs; first to directly drug important, previously undruggable solid tumor oncology target Strong...

BioXcel Therapeutics Reports First Quarter 2024 Financial Results

Written by Customer Service on May 9, 2024. Posted in Earnings Releases And Operating Results.

Advancing TRANQUILITY and SERENITY program plans for two pivotal Phase 3 trials to expand BXCL501 market potential in acute treatment of agitation Strengthened intellectual property portfolio for BXCL501 with grant of two new patents, in Japan and the U.S. Completed $25 million registered direct offering Conference call set for 8:00 a.m. ET today NEW HAVEN, Conn., May 09, 2024 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced its financial results for the first quarter of 2024. “The fundamentals of our business are strong as we look to continue advancing and expanding our agitation portfolio,” said Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics. “We have designed...

LanzaTech Announces First Quarter 2024 Financial Results and Reiterates Full Year 2024 Outlook

Written by Customer Service on May 9, 2024. Posted in Earnings Releases And Operating Results.

Achieved total revenue of $10.2 million for first quarter 2024 in-line with annual guidance and consistent with outlook of back-end weighted full year 2024 revenue Reiterating full year 2024 outlook including total revenue of $90 – $105 million Cash, restricted cash, and investments of $92.3 million at March 31, 2024 CHICAGO, May 09, 2024 (GLOBE NEWSWIRE) — LanzaTech Global, Inc. (Nasdaq: LNZA) (“LanzaTech” or the “Company”), the carbon recycling company transforming waste carbon into sustainable raw materials, today reported its financial and operating results for the first quarter 2024 and reiterated its previously issued financial outlook for full year 2024. “We delivered first quarter financial results in-line with our previously issued annual guidance, while achieving a key milestone with Project SECURE, showcasing...

Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Written by Customer Service on May 9, 2024. Posted in Public Companies.

Initial Phase 2 data of BDTX-1535 in 2L/3L EGFRm NSCLC patients on track for Q3 2024 Enrollment ongoing in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC; initial data expected Q1 2025 Presented real world evidence on the evolving EGFR mutation landscape in NSCLC, and the potential of BDTX-1535 across multiple lines of therapy at the 2024 AACR annual meeting Poster presentations upcoming June 1st at 2024 ASCO Annual Meeting on BDTX-1535 in GBM patients: Phase 1 dose-escalation data and initial “window of opportunity” trial results Cash, cash equivalents, and investments of $115.2 million as of March 31, 2024, expected to be sufficient to fund operations into Q3 of 2025CAMBRIDGE, MA, May 09, 2024 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing...

SPS Commerce Acquires Traverse Systems

Written by Customer Service on May 9, 2024. Posted in Mergers And Acquisitions.

Acquisition expands company’s product portfolio in supply chain performance and optimization Company to host conference call today at 8:30 a.m. ET MINNEAPOLIS, May 09, 2024 (GLOBE NEWSWIRE) — SPS Commerce, Inc. (NASDAQ: SPSC), a leader in retail supply chain cloud services, today announced the acquisition of Traverse Systems, an industry leading SaaS platform that provides retailers and their merchandise suppliers a unified view of supply chain performance to improve collaboration and enhance the consumer experience. Traverse Systems provides scorecarding and vendor performance management solutions for retailers, driving supply chain efficiencies such as increased on-time and in-full shipments, enhanced inventory accuracy, greater visibility into inbound shipments, real-time disruption management, and improved invoice accuracy. “Retailers...

Vital Farms Reports First Quarter 2024 Financial Results

Written by Customer Service on May 9, 2024. Posted in Earnings Releases And Operating Results.

Record First Quarter Net Revenue of $147.9 million, up 24.1% versus Prior Year PeriodRaises Fiscal Year 2024 OutlookAnnounces Plans for New State-of-the-Art Egg Washing and Packing Facility AUSTIN, Texas, May 09, 2024 (GLOBE NEWSWIRE) — Vital Farms (Nasdaq: VITL), a Certified B Corporation that offers a range of ethically produced foods nationwide, today reported financial results for its first quarter ended March 31, 2024. Financial highlights for the first quarter ended March 31, 2024, compared to the first quarter ended March 26, 2023, include:Net Revenue increased 24.1% to a record $147.9 million, compared to $119.2 million Gross Margin expanded 400 basis points to 39.8%, compared to 35.8% Net Income of $19.0 million, compared to $7.2 million Net Income per Diluted Share of $0.43, compared to $0.16 Adjusted EBITDA of $29.1...

Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

Written by Customer Service on May 9, 2024. Posted in Earnings Releases And Operating Results.

PDUFA Target Action Date for Ensifentrine of June 26, 2024 Finalizing commercial launch preparations Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., May 09, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the first quarter ended March 31, 2024, and provides a corporate update. “As we approach the PDUFA target action date for ensifentrine of June 26, we are finalizing our preparations for a potential US launch in the third quarter of 2024,” said David Zaccardelli, Pharm. D., President and Chief Executive Officer. “If approved, ensifentrine is expected to be the first novel inhaled mechanism...

Standard Lithium Reports Fiscal Third Quarter 2024 Results, Schedules Investor Update Call

Written by Customer Service on May 9, 2024. Posted in Earnings Releases And Operating Results.

STRATEGIC EXECUTION SECURES LEADING GLOBAL ENERGY PARTNER, EQUINOR. INJECTS IMMEDIATE LIQUIDITY THROUGH DIRECT INVESTMENTS IN SOUTH WEST ARKANSAS AND EAST TEXAS PROJECTS PARTNERSHIP BRINGS WORLD-CLASS PROJECT DEVELOPMENT CAPABILITIES, ACCELERATING SMACKOVER DEVELOPMENT PATH VANCOUVER, British Columbia, May 09, 2024 (GLOBE NEWSWIRE) — Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV:SLI) (NYSE American:SLI) (FRA:S5L), a leading near-commercial lithium development company, today reported its financial and operating results for the fiscal third quarter ended March 31, 2024. “In Q3, Standard Lithium continued to execute on our strategic plan, responsibly and efficiently advancing our projects,” stated Standard Lithium CEO Robert Mintak. “While the lithium sector has experienced challenges over the past year,...

Xometry Reports First Quarter 2024 Results

Written by Customer Service on May 9, 2024. Posted in Earnings Releases And Operating Results.

Q1 revenue increased 16% year-over-year to $123 million driven by marketplace growth of 24% year-over-year. Q1 gross profit increased 22% year-over-year driven by 37% growth in marketplace gross profit. Q1 marketplace gross margin increased 320 basis points year-over-year to a record 32.0%. Q1 Adjusted EBITDA loss of $7.5 million, a 37% improvement year-over-year driven by higher revenue, gross profit, and operating efficiencies. 2024 growth initiatives include: expanding buyer and supplier networks; driving deeper enterprise engagement; expanding the marketplace menu; growing internationally and enhancing supplier services.NORTH BETHESDA, Md., May 09, 2024 (GLOBE NEWSWIRE) — Xometry, Inc. (NASDAQ:XMTR), the global AI-powered marketplace connecting enterprise buyers with suppliers of manufacturing services, today reported financial...

HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights

Written by Customer Service on May 9, 2024. Posted in Earnings Releases And Operating Results.

Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligns with U.S. Food and Drug Administration (FDA) feedback HB-200 program received Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) Received FDA clearance for Investigational New Drug (IND) application for HB-700 for the treatment of KRAS mutated cancers NEW YORK and VIENNA, May 09, 2024 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and recent business highlights for the first quarter of 2024. “The first quarter was about focus at HOOKIPA. We are embarking on a pivotal trial...

Month: May 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals